


Summary of the invention

It is therefore the object of the present invention to provide compounds, which bind to the orphan nuclear receptors ROR γ 1 and/or ROR γ t and, thus, to open new methods for treating diseases associated with the modulation of ROR γ , such as autoimmune diseases, inflammatory skin diseases or multiple sclerosis.

This object is solved by claims 1 to 224.

In a first aspect of the present disclosure, there is provided a compound represented by Formula (1) to Formula (5)



an enantiomer, diastereomer, tautomer, *N*-oxide, solvate, formulation and pharmaceutically acceptable salt thereof,

wherein

R¹ is independently selected from C₁₋₁₀-alkyl, C₂₋₁₀-alkenyl, C₂₋₁₀-alkynyl, C₃₋₁₀-cycloalkyl, C₃₋₁₀-heterocycloalkyl, C₁₋₁₀-alkylene-C₃₋₁₀-cycloalkyl, C₁₋₁₀-alkylene-C₃₋₁₀-heterocycloalkyl, C₁₋₁₀-alkylene-(5-membered heteroaryl) and SO₂-C₁₋₁₀-alkyl, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, CN, OR¹¹, O-C₂₋₆-alkylene-OR¹¹, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, halogen, CO₂R¹¹, CONR¹¹R¹², CONR¹¹SO₂R¹¹, COR¹¹, SO_xR¹¹, SO₃H, SO₂NR¹¹R¹², NR¹¹COR¹¹, NR¹¹SO₂R¹¹, NR¹¹-CO-NR¹¹R¹², NR¹¹-SO₂-NR¹¹R¹², C₃₋₁₀-cycloalkyl, O-C₃₋₁₀-cycloalkyl, C₃₋₁₀-heterocycloalkyl, O-C₃₋₁₀-heterocycloalkyl and NR¹¹R¹²,

R² is R¹ or H;

or R¹ and R² when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, oxo, CN, OR¹¹, SO_xR¹¹, SO₃H, NR¹¹SO₂R¹¹, SO₂NR¹¹R¹², C₀₋₆-alkylene-CO₂R¹¹, CONR¹¹R¹², CONR¹¹SO₂R¹¹, COR¹¹, NR¹¹-CO-R¹¹, NR¹¹-CO-NR¹¹R¹², NR¹¹-SO₂-NR¹¹R¹², NR¹¹R¹², C₁₋₆-alkyl, halo-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, C₃₋₈-cycloalkyl, O-C₃₋₈-cycloalkyl, C₃₋₈-heterocycloalkyl and O-C₃₋₈-heterocycloalkyl,

wherein cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C₁₋₃-alkyl, halo-C₁₋₃-alkyl, OH, O-C₁₋₃-alkyl, O-halo-C₁₋₃-alkyl, SO₂-C₁₋₃-alkyl, COOH and oxo;

R³ is a 6-10 membered mono- or bicyclic aryl or a 5-14 membered mono-, bi- or tricyclic heteroaryl containing 1 to 5 heteroatoms independently selected from the group consisting of N, O and S,

wherein aryl and heteroaryl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, C₁₋₆-alkyl, C₂₋₆-alkenyl, C₂₋₆-alkynyl, halo-C₁₋₆-alkyl, OH, O-C₁₋₆-alkyl, O-halo-C₁₋₆-alkyl, C₀₋₆-alkylene-C₃₋₁₀-cycloalkyl, C₀₋₆-alkylene-C₃₋₁₀-heterocycloalkyl, C₀₋₆-alkylene-(5- or 6-membered heteroaryl), C₁₋₆-alkylene-O-R³¹, C₀₋₆-alkylene-CN, C₀₋₆-alkylene-N(R³¹)₂, O-C₃₋₁₀-cycloalkyl, O-C₁₋₆-alkylene-O-R³¹, O-C₃₋₁₀-heterocycloalkyl, C₀₋₆-alkylene-COOR³¹, C₀₋₆-alkylene-C(O)R³¹, C₀₋₆-alkylene-C(O)N(R³¹)₂, C₀₋₆-alkylene-N(R³¹)C(O)R³¹, C₀₋₆-alkylene-SO-R³¹, C₀₋₆-alkylene-SO₂-R³¹, C₀₋₆-alkylene-SO₂-N(R³¹)₂, C₀₋₆-alkylene-N(R³¹)SO₂-R³¹, C₀₋₆-alkylene-SO₂-C₃₋₁₀-heterocycloalkyl and C₀₋₆-alkylene-SO₂-C₃₋₁₀-heterocycloalkyl,

wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl and the 5- or 6-membered heteroaryl is unsubstituted or substituted by 1 to 4 substituents independently selected from the group consisting of halogen, CN, C₁₋₃-alkyl, halo-C₁₋₃-alkyl, OH, oxo, =N-OR³², O-C₁₋₃-alkyl and O-halo-C₁₋₃-alkyl,

or wherein two adjacent substituents complete a 3- to 8-membered saturated or partially unsaturated ring containing carbon atoms and optionally containing 1 to 3 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of halogen, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, C₃₋₆-cycloalkyl, C₃₋₆-heterocycloalkyl, oxo, =N-OR³², OH, O-C₁₋₆-alkyl and O-halo-C₁₋₆-alkyl;

R⁴ is (CR⁸R⁹)R⁴⁰, (C=O)R⁴⁰, (C=O)NR¹³R¹⁴, O-R⁴⁰, C₃₋₁₀-cycloalkylidenemethyl, C₃-cycloalkylene-R⁴⁰ or SO_y-R⁷;

R⁵ is H, C₁₋₃-alkyl, C₃₋₆-cycloalkyl or halo-C₁₋₃-alkyl,

wherein alkyl, cycloalkyl and haloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of OH, oxo, O-C₁₋₆-alkyl and O-halo-C₁₋₆-alkyl;

R⁶ is independently H, halogen, CN, C₁₋₃-alkyl, C₃₋₆-cycloalkyl, halo-C₁₋₃-alkyl or CONHR⁶¹R⁶²,

wherein alkyl, cycloalkyl and haloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of OH, oxo, O-C₁₋₆-alkyl and O-halo-C₁₋₆-alkyl;

R⁷ is C₃₋₁₀-cycloalkyl or C₃₋₁₀-heterocycloalkyl,

wherein cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, oxo, O-C₁₋₆-alkyl, O-halo-C₁₋₆-alkyl, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, C₃₋₇-cycloalkyl and 3 to 7-membered heterocycloalkyl;

R⁸ is H, F, C₁₋₃-alkyl, halo-C₁₋₃-alkyl, OH, O-C₁₋₃-alkyl or O-halo-C₁₋₃-alkyl;

R⁹ is H, F, C₁₋₃-alkyl or halo-C₁₋₃-alkyl;

R¹¹ is independently selected from H, C₁₋₆-alkyl, C₀₋₆-alkylene-C₃₋₁₀-cycloalkyl and C₀₋₆-alkylene-C₃₋₁₀-heterocycloalkyl,

wherein alkyl, alkylene, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 6 substituents selected from the group consisting of halogen, CN, OH, oxo, C₁₋₃-alkyl, halo-C₁₋₃-alkyl, O-C₁₋₃-alkyl, O-halo-C₁₋₃-alkyl, NH₂, NH(C₁₋₃-alkyl), N(C₁₋₃-alkyl)₂, C₃₋₆-heterocycloalkyl, C₃₋₆-cycloalkyl and SO₂-C₁₋₃-alkyl,

wherein cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, OH, oxo, CH₃ and CF₃;

R¹² is independently selected from H, C₁₋₆-alkyl, halo-C₁₋₆-alkyl and C₃₋₆-cycloalkyl;

R¹³ and R¹⁴ taken together with the nitrogen to which they are attached complete a 3- to 10-membered ring containing carbon atoms, wherein this ring is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, O-C₁₋₆-alkyl, O-halo-C₁₋₆-alkyl, C₁₋₆-alkyl, halo-C₁₋₆-alkyl and C₃₋₆-cycloalkyl;

R³¹ is independently selected from H, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, C₀₋₆-alkylene-C₃₋₈-cycloalkyl, C₀₋₆-alkylene-C₃₋₈-heterocycloalkyl, 5- or 6-membered heteroaryl and 6-membered aryl,

wherein alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of halogen, CN, OH, oxo, =N-OR³², C₁₋₃-alkyl, halo-C₁₋₃-alkyl, O-C₁₋₃-alkyl, O-halo-C₁₋₃-alkyl and SO₂-C₁₋₃-alkyl;

and optionally when two R³¹ are attached to a nitrogen atom, they may complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4

substituents independently selected from the group consisting of fluoro, OH, oxo, C₁₋₄-alkyl and halo-C₁₋₄-alkyl;

R³² is independently selected from H, C₁₋₆-alkyl, halo-C₁₋₆-alkyl and C₃₋₆-cycloalkyl;


R⁴⁰ is C₃₋₁₀-cycloalkyl, which is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, O-C₁₋₆-alkyl, O-halo-C₁₋₆-alkyl, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, C₃₋₈-cycloalkyl and C₃₋₈-heterocycloalkyl;

R⁶¹ and R⁶² are independently selected from the group consisting of H, C₁₋₃-alkyl and halo-C₁₋₃-alkyl;

x and y is independently selected from 0, 1 and 2;

with the proviso that compound 5-(cyclopentylmethyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide is excluded and compounds of Formula (5), wherein R⁴ is OR⁴⁰ are excluded.

In a second aspect of the present disclosure, there is provided a compound according to Formula (6) to Formula (9)



an enantiomer, diastereomer, tautomer, solvate, formulation and pharmaceutically acceptable salt thereof,

wherein

Q¹ is CO-NR⁵¹R⁵², CO-R⁵², CO₂R⁵¹, SO₂-NR⁵¹R⁵², SO₂-R⁵², NR⁵²CO-R⁵¹ or NR⁵²SO₂-R⁵¹,

Q² and Q³ are independently selected from N and CR⁵⁶;

R⁵¹ and R⁵² are independently selected from the group consisting of H, C₁₋₁₀-alkyl, C₂₋₁₀-alkenyl, C₂₋₁₀-alkynyl, C₀₋₁₀-alkylene-C₃₋₁₀-cycloalkyl, C₀₋₁₀-alkylene-C₃₋₁₀-heterocycloalkyl, C₀₋₁₀-alkylene 5 to 10-membered heteroaryl and C₀₋₁₀-alkylene-aryl, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, CN, OR⁶¹, O-C₂₋₆-alkylene-OR⁶¹, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, halogen, CO₂R⁶¹, CONR⁶¹R⁶², CONR⁶¹SO₂R⁶², COR⁶¹, SO_xR⁶¹, SO₃H, SO₂NR⁶¹R⁶², NR⁶¹COR⁶¹, NR⁶¹SO₂R⁶¹, NR⁶¹-CO-NR⁶¹R⁶², NR⁶¹-SO₂-NR⁶¹R⁶², C₃₋₆-cycloalkyl, O-C₃₋₆-cycloalkyl, C₃₋₆-heterocycloalkyl, O-C₃₋₆-heterocycloalkyl and NR⁶¹R⁶²,

or R⁵¹ and R⁵² when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2

heteroatoms independently selected from the group consisting of O, S and N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, oxo, CN, OR⁶¹, SO_xR⁶¹, SO₃H, NR⁶¹SO₂R⁶¹, SO₂NR⁶¹R⁶², CO₂R⁶¹, CONR⁶¹R⁶², CONR⁶¹SO₂R⁶², COR⁶¹, NR⁶¹-CO-R⁶¹, NR⁶¹-CO-NR⁶¹R⁶², NR⁶¹-SO₂-NR⁶¹R⁶², NR⁶¹R⁶², C₁₋₆-alkyl, halo-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, C₃₋₆-cycloalkyl, O-C₃₋₆-cycloalkyl, C₃₋₆-heterocycloalkyl and O-C₃₋₆-heterocycloalkyl;

R⁵³ is a 6-10 membered mono- or bicyclic aryl or a 5-14 membered mono-, bi- or tricyclic heteroaryl containing 1 to 5 heteroatoms independently selected from the group consisting of N, O and S,

wherein aryl and heteroaryl are unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, CN, C₁₋₆-alkyl, C₂₋₆-alkenyl, C₂₋₆-alkynyl, halo-C₁₋₆-alkyl, OH, O-C₁₋₆-alkyl, O-halo-C₁₋₆-alkyl, C₀₋₆-alkylene-C₃₋₁₀-cycloalkyl, C₀₋₆-alkylene-O-C₃₋₁₀-cycloalkyl, C₀₋₆-alkylene-C₃₋₁₀-heterocycloalkyl, C₀₋₆-alkylene-COOR⁸¹, C₀₋₆-alkylene-C(O)R⁸¹, C₀₋₆-alkylene-C(O)N(R⁸¹)₂, C₀₋₆-alkylene-N(R⁸¹)₂, C₀₋₆-alkylene-SO₂-N(R⁸¹)₂, C₀₋₆-alkylene-SO₂-R⁸¹, C₀₋₆-alkylene-(6-10-membered mono- or bicyclic aryl), and C₀₋₆-alkylene-(6-10-membered mono- or bicyclic heteroaryl),

wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl and heteroaryl are unsubstituted or substituted by 1 to 3 substituents independently selected from the group consisting of C₁₋₆-alkyl, halo-C₁₋₆-alkyl, halogen, OH, oxo, =N-OR⁸², N(R⁸¹)₂, O-C₁₋₆-alkyl, O-halo-C₁₋₆-alkyl, COOH, CON(R⁸¹)₂, CN, NR⁸¹-COR⁸¹, C₃₋₁₀-cycloalkyl, C₃₋₁₀-heterocycloalkyl, 6-10-membered mono- or bicyclic aryl, and 6-10-membered mono- or bicyclic heteroaryl,

or wherein two adjacent substituents may complete a 4- to 8-membered saturated or partially unsaturated ring containing carbon atoms and optionally containing 1 to 3 members selected from the group consisting of O, S, SO, SO₂ and NR⁸¹, wherein the ring is unsubstituted or substituted with 1 to 4r substituents independently selected from the group consisting of halogen, oxo, =N-OR⁸², OH, O-C₁₋₆-alkyl, O-halo-C₁₋₆-alkyl, C₁₋₆-alkyl, C₃₋₆-cycloalkyl and halo-C₁₋₆-alkyl;

R⁵⁴ is C₀₋₆-alkylene-R⁵⁷, C₃-cycloalkyl-R⁵⁷, O-C₀₋₅-alkylene-R⁵⁷, NR⁹¹-C₀₋₅-alkylene-R⁵⁷ and SO_x-C₀₋₅-alkylene-R⁵⁷,

wherein alkylene is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, =N-OR⁸², N(R⁸¹)₂, O-C₁₋₆-alkyl, COOH, CON(R⁸¹)₂, CN, NR⁸¹-COR⁸¹, C₃₋₆-cycloalkyl and C₃₋₆-heterocycloalkyl;

R⁵⁵ is independently selected from H, C₁₋₆-alkyl and C₃₋₆-cycloalkyl,

wherein alkyl and cycloalkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, O-C₁₋₃-alkyl; O-halo-C₁₋₃-alkyl and C₃₋₆-cycloalkyl;

R⁵⁶ is independently selected from the group consisting of H, halogen, CN, C₁₋₆-alkyl, C₃₋₆-cycloalkyl, O-C₁₋₆-alkyl and CONHR⁶¹R⁶²,

wherein alkyl and cycloalkyl is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, O-C₁₋₃-alkyl; O-halo-C₁₋₃-alkyl and C₃₋₆-cycloalkyl;

R⁵⁷ is C₁₋₁₀-alkyl, C₃₋₁₀-cycloalkyl, C₃₋₁₀-heterocycloalkyl, 6-10-membered mono- or bicyclic aryl or 6-10-membered mono- or bicyclic heteroaryl,

wherein alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, oxo, O-C₁₋₆-alkyl, O-halo-C₁₋₆-alkyl, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, C₃₋₁₀-cycloalkyl and 5 to 10-membered heterocycloalkyl;

R⁶¹ and R⁶¹ are independently selected from the group consisting of H, C₁₋₆-alkyl, C₃₋₁₀-cycloalkyl, C₃₋₁₀-heterocycloalkyl, phenyl, 5-6-membered heteroaryl containing 1 to 4 heteroatoms independently selected from the group consisting of N, O and S

wherein alkyl, cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of C₁₋₆-alkyl, halo-C₁₋₆-alkyl, OH, O-C₁₋₆-alkyl, O-halo-C₁₋₆-alkyl, phenyl, 5 to 10-membered heteroaryl, halogen, NH₂, NH(C₁₋₆-alkyl), N(C₁₋₆-alkyl)₂, C₃₋₁₀-heterocycloalkyl, C₃₋₁₀-cycloalkyl, SO₂-C₁₋₃-alkyl, oxo, and CN,

wherein cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of C₁₋₆-alkyl, halo-C₁₋₆-alkyl, OH, O-C₁₋₆-alkyl, O-halo-C₁₋₆-alkyl, phenyl, 5 to 6-membered heteroaryl, halogen, NH₂, NH(C₁₋₆-alkyl), N(C₁₋₆-alkyl)₂ and C₃₋₁₀-cycloalkyl,

wherein phenyl and heteroaryl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of OH, O-C₁₋₆-alkyl, O-halo-C₁₋₆-alkyl, halogen, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, NH₂, NH(C₁₋₆-alkyl), N(C₁₋₆-alkyl)₂ and C₃₋₁₀-cycloalkyl;

R⁶² and R⁶² are independently selected from the group consisting of H, C₁₋₆-alkyl, halo-C₁₋₆-alkyl and C₃₋₁₀-cycloalkyl;

R⁹¹ is H, C₁₋₆-alkyl, C₃₋₆-cycloalkyl or C₃₋₆-heterocycloalkyl,

wherein alkyl, cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of OH, oxo, CN, halogen, O-C₁₋₆-alkyl, O-halo-C₁₋₆-alkyl, C₃₋₆-heterocycloalkyl and C₃₋₆-cycloalkyl;

x is independently selected from 0, 1 and 2;

for use in the treatment or prophylaxis of a disease or disorder associated with the inhibition or activation of the ROR γ receptor.

In a third aspect of the present disclosure, there is provided the compound according to the first aspect as medicament.

In a fourth aspect of the present disclosure, there is provided the compound according to the first aspect for use in the treatment or prophylaxis of a disease or disorder associated with the inhibition or activation of the ROR γ receptor.

In a fifth aspect of the present disclosure, there is provided a pharmaceutical composition comprising a compound according to any of the first or second aspects and a pharmaceutically acceptable carrier or excipient.

In a sixth aspect of the present disclosure, there is provided a use of the compound according to the first aspect for the manufacture of a medicament for the treatment or prophylaxis of a disease or disorder associated with the inhibition or activation of the ROR γ receptor.

Thus, the present ~~invention~~disclosure provides carboxamide containing cyclic compounds as ROR γ modulators, which can be used for treating or preventing a disease or disorder associated with the inactivation or activation of the ROR γ receptor.

The present ~~invention~~disclosure relates to a ROR γ modulator which is based on a cyclic scaffold for use in the treatment or prophylaxis of a disease or disorder associated with the inhibition or activation of ROR γ .

When treating the disease or disorder associated with the modulation of the ROR γ receptor, the activity of said receptor is preferably reduced.

Preferably, the disease or disorder is selected from the group consisting of autoimmune diseases. Autoimmune diseases comprise a group of diseases with a similar etiology of an overshooting immune response against endogenous targets resulting in chronic inflammation and physical disabilities or other severe symptoms. Autoimmune diseases comprise e.g. rheumatoid arthritis, ankylosing spondylitis, lupus erythematosus, psoriasis, psoriatic arthritis, atopic eczema, inflammatory bowel diseases such as Crohn's disease, asthma, mucosal leishmaniasis, multiple sclerosis, systemic sclerosis, type 1 diabetes, Kawasaki disease, Hashimoto's thyroiditis, chronic graft-versus-host disease, acute graft-versus-host disease, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjorgren's syndrome, scleroderma, ulcerative colitis, epidermal hyperplasia, glomerulonephritis, chronic obstructive pulmonary disease (COPD) and amyotrophic lateral sclerosis.

The present ~~invention~~disclosure provides novel compounds to be used in the treatment of diseases or disorders associated with the inactivation or activation of the ROR γ receptor.

Further, the present ~~invention~~disclosure relates to a method for treating autoimmune diseases comprising rheumatoid arthritis, ankylosing spondylitis, lupus erythematosus, psoriasis, psoriatic arthritis, atopic eczema, inflammatory bowel diseases such as Crohn's disease, asthma, mucosal leishmaniasis, multiple sclerosis, systemic sclerosis, type 1 diabetes, Kawasaki disease, Hashimoto's thyroiditis, chronic graft-versus-host disease, acute graft-versus-host disease, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjorgren's syndrome, scleroderma, ulcerative colitis, epidermal hyperplasia, glomerulonephritis, chronic obstructive pulmonary disease and amyotrophic

19. The compound according to any of claims 1 to 11 for use in the treatment or prophylaxis of a disease or disorder associated with the inhibition or activation of the ROR γ receptor.

20. The compound for use according to claim 19, wherein the disease is selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, lupus erythematosus, psoriasis, psoriatic arthritis, atopic eczema, inflammatory bowel diseases such as Crohn's disease, asthma, mucosal leishmaniasis, multiple sclerosis, systemic sclerosis, type 1 diabetes, Kawasaki disease, Hashimoto's thyroiditis, chronic graft-versus-host disease, acute graft-versus-host disease, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjorgren's syndrome, scleroderma, ulcerative colitis, epidermal hyperplasia, glomerulonephritis, chronic obstructive pulmonary disease and amyotrophic lateral sclerosis.

21. A pharmaceutical composition comprising a compound according to any of claims 1 to 17 and a pharmaceutically acceptable carrier or excipient.

22. The compound for use according to any of claims 12 to 17, wherein the disease or disorder is selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, lupus erythematosus, psoriasis, psoriatic arthritis, atopic eczema, inflammatory bowel diseases such as Crohn's disease, asthma, mucosal leishmaniasis, multiple sclerosis, systemic sclerosis, type 1 diabetes, Kawasaki disease, Hashimoto's thyroiditis, chronic graft-versus-host disease, acute graft-versus-host disease, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjorgren's syndrome, scleroderma, ulcerative colitis, epidermal hyperplasia, glomerulonephritis, chronic obstructive pulmonary disease and amyotrophic lateral sclerosis.

23. Use of the compound according to any of claims 1 to 11 for the manufacture of a medicament for the treatment or prophylaxis of a disease or disorder associated with the inhibition or activation of the ROR γ receptor.

24. Use according to claim 23, wherein the disease is selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, lupus erythematosus, psoriasis, psoriatic arthritis, atopic eczema, inflammatory bowel diseases such as Crohn's disease, asthma, mucosal leishmaniasis, multiple sclerosis, systemic sclerosis, type 1 diabetes, Kawasaki disease, Hashimoto's thyroiditis, chronic graft-versus-host disease, acute graft-versus-host disease, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjorgren's syndrome, scleroderma, ulcerative colitis, epidermal hyperplasia, glomerulonephritis, chronic obstructive pulmonary disease and amyotrophic lateral sclerosis.